Seeking Alpha

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee ...

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics (TGTX), Inc. , today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ...
Business Wire

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of the ...
Business Wire

Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from two pivotal Phase 3 trials of the ...
Seeking Alpha

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple ...

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics (TGTX), Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, ...